Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
Oric gets a reality check
Rinzimetostat efficacy wanes further as the company moves into phase 3.
FDA red and green lights: March 2026
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Merck vs Merck in late-line kidney cancer
The group wants to improve on its own Welireg in a new phase 3 trial.
